Skip to main content
Premium Trial:

Request an Annual Quote

Sequitur, BMS Expand Collaboration to Include RNAi

NEW YORK, March 3 - Sequitur said today that it has expanded an existing agreement with Bristol-Myers Squibb to include work with RNAi.

 

Sequitur said it is now entering the fourth year of the existing collaboration, under which it has been performing biological screening assays for target validation. Under the expanded agreement, the company will also provide BMS with RNAi -- a form of double-stranded RNA that causes sequence-specific inhibition of target mRNAs -- for use in target validation studies.

 

In January 2001, Sequitur agreed to provide BMS with antisense compounds for target validation.

 

Sequitur's other clients include Incyte Genomics, GlaxoSmithKline, Pfizer, Genentech, Procter and Gamble, Harvard University, the Mayo Clinic, Scripps, Roche, Schering-Plough, and Wyeth.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.